Marksans Pharma has informed that the meeting of the Board of Directors of the Company is scheduled on 19/05/2025, to consider and approve the Audited Financial Results of the Company (both Standalone and Consolidated) for the Quarter and Year ended March 31, 2025; To consider recommendation of dividend on the equity shares for the financial year 2024-25, if any.
The above information is a part of company’s filings submitted to BSE.